CAJ | 학술논문

恶性黑素瘤由于其侵袭性强,预后较差,目前在世界范围内仍是尚未攻克的难题之一.研究发现,抗CTLA-4单克隆抗体能显著提高黑素瘤患者平均生存期和客观有效率,是一种新型的依靠免疫作用的靶向治疗药物.这一研究指明干涉抑制性免疫调节点在肿瘤免疫治疗中具有重要作用,为晚期黑素瘤治疗研究提供了新的探索方向和治疗思路.
악성흑소류유우기침습성강,예후교차,목전재세계범위내잉시상미공극적난제지일.연구발현,항CTLA-4단극륭항체능현저제고흑소류환자평균생존기화객관유효솔,시일충신형적의고면역작용적파향치료약물.저일연구지명간섭억제성면역조절점재종류면역치료중구유중요작용,위만기흑소류치료연구제공료신적탐색방향화치료사로.
The treatment of malignant melanoma remains a difficult problem in the world because of its strong invasion and poor prognosis.It has been evidenced that anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies notably increase the average survival and objective response rate of patients with melanoma,and are considered to be a novel immune-based targeted therapeutic agent.The interference in inhibitory immune regulatory checkpoints has been demonstrated to play an important role in tumor immunotherapy,which may provide new directions and ideas for the treatment of advanced melanoma.